Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02017717 : A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
PhasePhase 3
AgesMin: 18 Years Max: N/A
Eligibility
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Subjects with histologically confirmed Grade IV malignant glioma

- Previous treatment with radiotherapy and temozolomide (Cohorts 1, 1b and 2 only)

- First recurrence of GBM (Cohorts 1, 1b and 2 only)

- First diagnosis of GBM with resectable disease (Cohorts 1c Part A only)

- First diagnosis of unmethylated MGMT GBM (Cohort 1d and Cohort 1c Part B only)

- Karnofsky performance score of 70 or higher

Exclusion Criteria:

- More than 1 recurrence of GBM (Cohorts 1, 1b and 2 only)

- Any recurrence of GBM (Cohorts 1c and 1d only)

- Presence of extracranial metastatic or leptomeningeal disease

- Active, known or suspected autoimmune disease

- Clinically significant cardiovascular disease

- Prior bevacizumab or other Vascular Endothelial Growth Factor (VEGF) or
anti-angiogenic treatment (Cohort 2 only)
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02017717      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740